Henk J. Broxterman

3.8k total citations
51 papers, 2.8k citations indexed

About

Henk J. Broxterman is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Henk J. Broxterman has authored 51 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 21 papers in Molecular Biology and 13 papers in Cancer Research. Recurrent topics in Henk J. Broxterman's work include Drug Transport and Resistance Mechanisms (13 papers), Renal cell carcinoma treatment (8 papers) and Angiogenesis and VEGF in Cancer (6 papers). Henk J. Broxterman is often cited by papers focused on Drug Transport and Resistance Mechanisms (13 papers), Renal cell carcinoma treatment (8 papers) and Angiogenesis and VEGF in Cancer (6 papers). Henk J. Broxterman collaborates with scholars based in Netherlands, United States and Israel. Henk J. Broxterman's co-authors include Henk M.W. Verheul, Yehuda G. Assaraf, Herbert M. Pinedo, Klaas Hoekman, Yoav D. Livney, Alina Shapira, Kristy J. Gotink, Godefridus J. Peters, Jan Lankelma and Rik J. Scheper and has published in prestigious journals such as Blood, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Henk J. Broxterman

51 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henk J. Broxterman Netherlands	26	1.4k	1.3k	470	379	342	51	2.8k
Giuseppe Corona Italy	30	1.7k 1.2×	1.1k 0.8×	503 1.1×	234 0.6×	328 1.0×	109	3.0k
Michelle J. Henderson Australia	21	1.6k 1.1×	1.1k 0.9×	442 0.9×	170 0.4×	183 0.5×	40	2.5k
Lucia Viganò Italy	23	1.3k 0.9×	1.4k 1.1×	695 1.5×	296 0.8×	248 0.7×	38	2.9k
Maja J.A. de Jonge Netherlands	33	1.7k 1.2×	1.5k 1.2×	267 0.6×	620 1.6×	182 0.5×	107	3.1k
David A. Van Echo United States	26	916 0.6×	1.5k 1.2×	171 0.4×	437 1.2×	400 1.2×	71	3.0k
Jill Kolesar United States	37	2.0k 1.4×	1.8k 1.4×	620 1.3×	936 2.5×	172 0.5×	192	4.3k
Stephanie L. Safgren United States	20	1.1k 0.8×	835 0.6×	441 0.9×	275 0.7×	226 0.7×	53	2.6k
Paul Noordhuis Netherlands	32	1.4k 1.0×	1.7k 1.3×	412 0.9×	506 1.3×	100 0.3×	82	3.4k
Herman Burger Netherlands	28	1.2k 0.8×	1.3k 1.0×	246 0.5×	330 0.9×	129 0.4×	45	2.6k
Hans Minderman United States	34	1.7k 1.2×	1.4k 1.1×	450 1.0×	187 0.5×	81 0.2×	90	3.2k

Countries citing papers authored by Henk J. Broxterman

Since Specialization

Citations

This map shows the geographic impact of Henk J. Broxterman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henk J. Broxterman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henk J. Broxterman more than expected).

Fields of papers citing papers by Henk J. Broxterman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henk J. Broxterman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henk J. Broxterman. The network helps show where Henk J. Broxterman may publish in the future.

Co-authorship network of co-authors of Henk J. Broxterman

This figure shows the co-authorship network connecting the top 25 collaborators of Henk J. Broxterman. A scholar is included among the top collaborators of Henk J. Broxterman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henk J. Broxterman. Henk J. Broxterman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Walraven, Maudy, Siamack Sabrkhany, Jaco C. Knol, et al.. (2021). Effects of Cancer Presence and Therapy on the Platelet Proteome. International Journal of Molecular Sciences. 22(15). 8236–8236. 15 indexed citations

Broxterman, Henk J., Siu W. Lam, Epie Boven, et al.. (2016). A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. British Journal of Cancer. 115(8). 940–948. 4 indexed citations

Mijn, Johannes C. van der, Mariëtte Labots, Sander R. Piersma, et al.. (2015). Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. Journal of Proteomics. 127(Pt B). 259–263. 39 indexed citations

Gotink, Kristy J., Henk J. Broxterman, Mariëtte Labots, et al.. (2011). Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical Cancer Research. 17(23). 7337–7346. 290 indexed citations

Veldt, Astrid A.M. van der, Richard R. de Haas, Pieter Koolwijk, et al.. (2011). Sunitinib‐induced changes in circulating endothelial cell‐related proteins in patients with metastatic renal cell cancer. International Journal of Cancer. 131(4). E484–93. 15 indexed citations

Shapira, Alina, Yoav D. Livney, Henk J. Broxterman, & Yehuda G. Assaraf. (2011). Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resistance Updates. 14(3). 150–163. 399 indexed citations

Broxterman, Henk J., Kristy J. Gotink, & Henk M.W. Verheul. (2009). Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resistance Updates. 12(4-5). 114–126. 185 indexed citations

Cruijsen, Hester van, Astrid A.M. van der Veldt, Dinja Oosterhoff, et al.. (2008). Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. Clinical Cancer Research. 14(18). 5884–5892. 111 indexed citations

Hensbergen, Yvette van, Henk J. Broxterman, Sareena Rana, et al.. (2004). Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts. Clinical Cancer Research. 10(3). 1180–1191. 44 indexed citations

10.

Broxterman, Henk J. & N H Georgopapadakou. (2004). New cancer therapeutics: target-specific in, cytotoxics out?. Drug Resistance Updates. 7(2). 79–87. 19 indexed citations

11.

Jong, Mariska C. de, George L. Scheffer, Henk J. Broxterman, et al.. (2003). Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.. PubMed. 9(13). 5009–17. 8 indexed citations

12.

Hensbergen, Yvette van, Erna Peters, Sareena Rana, et al.. (2003). Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix. Thrombosis and Haemostasis. 90(11). 921–929. 8 indexed citations

13.

Hensbergen, Yvette van, Henk J. Broxterman, Yvonne W. Elderkamp, et al.. (2002). A doxorubicin–CNGRC-peptide conjugate with prodrug properties. Biochemical Pharmacology. 63(5). 897–908. 70 indexed citations

14.

Broxterman, Henk J. & N H Georgopapadakou. (2001). Cancer research 2001: drug resistance, new targets and drug combinations. Drug Resistance Updates. 4(3). 197–209. 16 indexed citations

15.

Broxterman, Henk J. & N H Georgopapadakou. (2000). Cancer research 2000: drug resistance, new targets and drugs in development. Drug Resistance Updates. 3(3). 133–138. 4 indexed citations

16.

Flens, Marcel J., George L. Scheffer, Paul van der Valk, et al.. (1997). Identification of novel drug resistance–associated proteins by a panel of rat monoclonal antibodies. International Journal of Cancer. 73(2). 249–257. 20 indexed citations

17.

Giaccone, Giuseppe, J van Ark-Otte, Adi F. Gazdar, et al.. (1996). MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung. International Journal of Cancer. 66(6). 760–767. 51 indexed citations

18.

Giaccone, Giuseppe, J van Ark-Otte, Adi F. Gazdar, et al.. (1996). MRP is frequently expressed in human lung‐cancer cell lines, in non‐small‐cell lung cancer and in normal lung. International Journal of Cancer. 66(6). 760–767. 3 indexed citations

19.

Lankelma, J., et al.. (1994). Daunorubicin efflux against a concentration gradient in non‐P‐glycoprotein multidrug‐resistant lung‐cancer cells. International Journal of Cancer. 59(2). 275–281. 9 indexed citations

20.

Broxterman, Henk J., et al.. (1981). Cross-tolerance of dopamine metabolism to baclofen, γ-butyrolactone and HA-966 in the striatum and olfactory tubercle of the rat. Life Sciences. 28(9). 973–981. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact